) followed by a non-myeloablative 200 cGy total body irradiationbased allograft was designed in Seattle. 4 At a median follow-up of 12.1 years, we report long-term clinical outcomes of minimal residual disease (MRD) kinetics by qualitative PCR (nested-PCR) and real-time quantitative PCR (qPCR) on a cohort of newly diagnosed patients treated with the Seattle approach.
Between December 1999 and July 2009, 26 patients (Supplementary Table S1 ) with suitable diagnostic bone marrow (BM) specimens for immunoglobulin heavy-chain gene rearrangement (IGH) sequencing were prospectively monitored for MRD. Patients were induced with two to three courses of vincristine-adriamycin-dexamethasone-based regimens (20/26, 78%; ClinicalTrial.gov, NCT-00702247), with three courses of bortezomib-thalidomide-dexametasone (VTD; EudraCTNumber: 2007-003707-12; 2/26, 8%) or with four courses of lenalidomidedexamethasone (4/26, 14%; ClinicalTrial.gov, NCT01264315) followed by the tandem transplant approach. 4 No pre-emptive donor lymphocyte infusions or maintenance/consolidation treatment were allowed except for the four patients enrolled in protocol NCT01264315 who started lenalidomide-dexamethasone maintenance.
The centralized MRD laboratory staff were blinded to clinical findings. BM samples were collected at diagnosis, after the autograft, at 1, 3 and 6 months after the allograft and then every 6 months or as clinically indicated. Patient-specific IGH rearrangements were amplified and direct sequenced using consensus sense primers derived from the framework region (FR) FR1 or FR2 and a consensus anti-sense primer derived from FR4, as previously published. [5] [6] [7] [8] Qualitative nested-PCR for the IGH rearrangement was performed on genomic DNA as previously described and its sensitivity was 3.3x10 −6 (refs 5-8) . qPCR analysis was performed in all nested-PCR positive cases, when DNA leftovers were available, according to the Euro-MRD criteria. 6 [4] [5] [6] [7] [8] [9] [10] [11] [12] .
At the time of the allograft, 8/26 (31%) and 4/26 (15%) were in clinical complete remission (CR) and partial remission (PR), respectively (Supplementary Data). Twelve additional patients (46%) achieved CR and one patient PR after the allograft (overall response 96%). At a median follow-up of 12.1 (6.52-15.2) years from diagnosis and 11.1 (5.5-14.2) years from the allograft, median overall survival (OS) was not reached and event-free survival (EFS) was 4 years. Cumulative incidence of relapse was 3.8% at 1 years, 30.8% at 2 years and 34.6% at 5 years. Interestingly, 5/26 (19%) patients relapsed with extra-medullary disease. Cumulative incidence of grade II-IV graft-vs-host disease (GVHD) and chronic GVHD were 26.9% and 65.4%, respectively. MRD studies showed that, after the autograft, 3/19 patients (16%) were nested-PCR negative. After the allograft, the rate of PCR negativity remained low at month 1 and 3 (5/19, 26% and 3/19, 16%, respectively); then increased up to 44% (8/18) at month 6 and 47% (7/15) at 1 year post-transplant (Table 1) . Among the seven patients with persistent nested-PCR negativity, only one clinical relapse was observed (10 months after the last MRD determination), whereas 7/12 patients who did not reach MR relapsed ( Figure 1 ). By qPCR analysis, overall tumor shrinkage throughout treatment resulted in 13.80 natural logarithm (ln) and always remarkable was tumor reduction after the autograft, the allograft and post-transplant graft-vs-myeloma (P o 0.001; Table 1 ). A median tumor burden reduction of 4.59 ln was seen after the autograft and a further decrease of 4.83 ln 1 month after the allograft. At 3 months, MRD levels were similar to those observed right after the allograft (+0.22 ln), whereas a further tumor reduction of 4.61 ln was observed at 6 months post-transplant. This finding was stable over time suggesting ongoing graft-vs-myeloma. At most time points, patients in continuous CR showed a lower median tumor burden as compared with those who relapsed (P o 0.001).
An important prognostic role of MR was observed. Overall MR occurred in 12/19 patients (63%). All patients in MR were also in CR. Median time to MR was 6 months (range: 1-18 months) and MR had a median duration of 27 months (range: 3-102 months) Letters to the Editor with seven patients in continuous MR and clinical CR. Patients who achieved MR showed a significantly lower incidence of relapse (27.1% vs 71.4% at median follow-up, P = 0.016) and better median EFS and OS (not reached vs 17.5 months, P = 0.010; not reached vs 40 months, P = 0.027, respectively) as compared with those who did not achieve MR (Figure 1, Supplementary Figure S1 ). Our study shows that our tandem approach induced high rates of prolonged MR by both qPCR and nested-PCR (63% and 47%, respectively). After a remarkable median follow-up of 12 years (range 6.5-15) from diagnosis, the achievement of MR by nested-PCR was significantly associated with better long-term OS and EFS, median durations of which had not yet been reached (Figure 1 ). Whether long-term persistence of MRD negativity coincides with disease eradication remains a matter of debate though MR of several years may cautiously suggest cure. With 'new drugs' survival has dramatically improved especially in good prognosis patients. 9 Figure 1. Long-term clinical outcomes after tandem auto-allo transplantation and according to molecular remission status. Probability of overall survival (a), event-free survival (b) and relapse (c) of the study cohort (26 patients) and of patients who reached MR either by nested-PCR or qPCR (no. 12) vs those who had persistent disease (no. 7). Median follow-up was 12 years from diagnosis and 11 years after the allograft.
However, the vast majority of our patients (78%) were treated on protocols that predated the 'new drugs' era and never received them either as induction or maintenance. Lenalidomide did not affect the achievement of MR in two patients with a molecular marker who received post-transplant maintenance on protocol NCT01264315. One did not achieve MR and progressed 3 months after the start of lenalidomide and the other reached MR before starting it and died of multi-organ failure 2 months later. These findings are consistent with persistent graft-vs-myeloma, potentially curative in a subset of patients. Moreover, there was no correlation between MRD status and chronic GVHD. Most patients had completely withdrawn the immuno-suppression that allowed high quality of life. At the time of this report, only two patients had remained on low-dose steroids to treat limited chronic GVHD. Overall, non-relapse mortality was 15% at 5 years. This underlines that, as for all other treatments, the lack of long-term disease control remains the principal cause of treatment failure after an allograft.
Importantly, our group also recently reported long-term outcomes of the GIMEMA-VEL-03-096 trial. 10 A cohort of 39 patients treated with VTD after an autograft were monitored for MRD with both nested-PCR and qPCR as in the present study. At a median follow-up of 8 years, OS was 72% for patients in MR response vs 48% for those with MRD persistence (P = 0.041). Moreover, 26 (67%) patients who achieved MR showed good disease control with median time-to-next therapy of 42 months whereas time-to-next therapy in patients with MRD reappearance and MRD persistence were 9 and 10 months, respectively, (P = 0.706). Importantly, both studies were carried out in the same facility by the same laboratory staff who were blinded to clinical data.
Thought results were controversial, most prospective comparative studies on autografting vs allografting were conducted before the era of new drugs. [11] [12] [13] [14] The annual reports of the European bone marrow transplantation activities have however shown a steady increase of the use of allografting in plasma cell dyscrasias. The role of the combination of 'new drugs' with graft-vs-myeloma has not yet been explored in well-designed prospective studies.
1 Interestingly, one comparative study showed higher response rates to salvage therapies in the allograft patients and significantly longer OS from relapse after the allograft than after a second autograft. 12 These findings support a strong synergy between donor T cells and new drugs.
In one Phase II clinical trial the feasibility of bortezomib within a reduced-intensity conditioning and given as maintenance was evaluated. 15 Sixteen high-risk patients relapsed after an autograft were enrolled. Nine/16 (56%) and 5/16 (31%) achieved CR and PR, respectively. Three-year cumulative incidence of non-relapse mortality, relapse and OS were 25, 54 and 41%, respectively. For the first time, this trial showed safety and efficacy of an intensified conditioning with a 'new drug' in poor prognosis patients. The concept of maintenance treatment after an allograft was also introduced. These findings led to the design of a prospective multicenter trial through the European Myeloma Network. The trial aims at optimizing clinical outcomes by reducing the risk of relapse and the incidence of GVHD with the integration of bortezomib and lenalidomide in the treatment schema. Candidates are high-risk myeloma patients, younger than 70 years, with early relapse after first-line treatment with new drugs and autografting. Preliminary data will be available shortly (Perez-Simon, personal communication).
Graft-vs-myeloma after non-myeloablative allografting determined prolonged rates of MR similar to those described after myeloablative allografting and higher than those recently reported after a planned treatment combination of an autograft with VTD consolidation. 10 In the light of our and of others results, it may become ethical to evaluate in newly designed clinical trials the combination of graft-vs-myeloma with novel agents in young high-risk and/or early relapsed patients where life expectancy is poor also in the era of new drugs. 
